Member Info for Muminr

This is the best outcome possible with no dilution.

( whoever said “Very big risk that GDR fails again, David takes the IP sell it and shareholders get left with nothing." That’s not right; It only secures the value of the loan plus £50k.)

Exactly Badboxer, GDR has no debt - a very positive aspect of the company.

SaintOdranski, are you saying you are not uncertain?!

"It will be very interesting to see how long it takes Credo to achieve regulatory approval."

In Singapore, I don't know. In the UK NHS? Any day now ; )

The UK NHS, Europe, Middle East and US is GDR's market Gloria. Credo's product appears to be inferior and only available at "research use only" level in Singapore. Bearing in mind how long it's taken GDR to to achieve regulatory approval and sales, Credo must be 4-5 years behind in trying to penetrate our market.

Absolutely Eureka; it’s strange that the BOD and chairman hadn’t managed to find such an alternative to the massive dilution . And they’ve only accepted DN’s offer under duress. It does give Roger’s theory credibility, that they tried to get mates in on the cheap to make huge profits, at the expense of existing shareholders.

As far as milestones go for shareholder percentage, the next threshold for DN would be 25%. This would enable a shareholder to block “special resolutions,” which require a 75% vote (e.g., changes to articles, winding up); minority veto power.

So either that is DN's goal, or he genuinely believes there's money to be made by holding more shares. Either way, it's good for the share price!

Amers, if you've signed an NDA with the company, you can GENERALLY reveal that fact without disclosing any of the content.

Thanks for your reply. You're absolutely right in that nobody should take advice on an anonymous BB. Yeah, I got the impression that you're very heavily invested. However, you seem more confident as of late and that piqued my interest. I hate to say it mate, but you sound as though you're pinning things more on hope rather than evidence. Anyway, I hope there's a way we can all get out of this without a loss.

Hi Amers, thanks for many of your recent posts. I don't have much choice but to wait, as I have been here for over 5 years. I think the real issue for LTHs with high averages like me (18p) is is it worth taking a final punt and averaging down?

Ah yes that one, thanks Lesh8. That was to announce a reduction in holding though, from 3.68% to 1.92%

Sorry folks, did I miss an RNS about Nortrust's holding? How do we know this?

I agree Gloria. Ian Gilham presided over all of this, including the the unexplained departure of Cheek; he should resign. Dr Miele is best in his role as CSO. Russ clearly doesn't have the financial acumen for his role, and should also go.

I hear what you're saying James Trader, this is certainly a period of uncertainty. However, it is telling that such a large portion of shareholder voted against the BOD. Many of us very long term holders are sick of the BOD's contemptuous treatment of us. At least the present situation presents an opportunity for change. We'll have to wait and see.

I also voted against all resolutions.

"The longer we wait for news on funding, the more I am hopeful..." Come on Junior, how long have you been here? Long waits have never been fruitful here.

Thanks for those posts Lionel and Busicat, I have no doubt that pharmacogenomics will revolutionise prescribing and we’ll wonder why people ever took medicines based on guesswork. I’m also convinced that the genedrive technology is impressive and second to none. What I’m increasingly sceptical about over the years here is the management’s business nous. The potential is massive and I can only live in hope.

I think it’s interesting that that post doesn’t refer to clopidogrel specifically but therapeutics in general. The potential is huge:

Cytochrome P450 2C19 (CYP2C19) metabolizes a wide range of drugs, including:

Antiplatelet Agents

• Clopidogrel (Plavix): Requires activation by CYP2C19 to be effective.

Proton Pump Inhibitors (PPIs)

• Omeprazole

• Esomeprazole

• Lansoprazole

• Pantoprazole: Primarily metabolized by CYP2C19.

Antidepressants

• Selective serotonin reuptake inhibitors (SSRIs): Citalopram, Escitalopram, Sertraline

• Tricyclic antidepressants: Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Doxepin, Trimipramine.

Antifungal Agents

• Voriconazole: Metabolized to inactive forms.

Benzodiazepines

• Diazepam

• Lorazepam

• Oxazepam

• Temazepam: Clearance affected by CYP2C19 activity.

Other Drugs

• Antiepileptics: Mephenytoin, Clobazam

• Antimalarial: Proguanil (activated to cycloguanil)

• Cannabidiol.

CYP2C19 activity varies among individuals due to genetic polymorphisms, influencing drug efficacy and safety.

All this recruitment is interesting. The company must be confident, or suicidal.

If a raise significantly discounted on the current SP was inevitable in the next quarter, surely the directors would not have bought recently in the unprecedented amounts that they did.

I think they must be confident about NHS Scotland’s decision and also perhaps specialist commissioning and FDA talks materialising into something before any raise.